Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: My thoughts

I thought so, too, when I read the announcement, and I also didn't like the Swartz angle. Long, long ago, Brian mentioned that it would be wise to keep an eye on PTSC's 5 million preferreds, which have yet to be issued but are fully authorized.

One scenario has TPL or another entity taking PTSC private, or reverse-merging. I'd like to think S&L are more or less in the same boat as retail is in this regard, b/c of the number of shares that they own. But since nearly all of what they own (if not all outright, considering the divy's pd thus far) is pure profit, they make a nice bundle if PTSC is dissolved even at the current share price. So do a lot of us, though not the bundle we're likely all hoping for (personally, I'd like to see a min. of $3-4/share, but that's just me). And if they or TPL got/shared the preferreds? What then of lowly retail?

And again, at these levels, even Mr. Pohl and the missus get a nice tidy sum from their stated holdings. And who's to say there isn't a nice tidy gold-plated parachute awaiting him and other bd. members?

Just wonderin' and s'posin.' Comments/corrections always welcome.

I do appreciate Pohl's term of service, and how he seemed to respond to shareholders' concerns, unlike previous CEOs. But the activity-less office, seemingly useless, to the tune of nearly 100K/year, bugs me for some reason.

JMHO.

Share
New Message
Please login to post a reply